Back

Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 1 Treatment HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Irene Mattavelli

Monzino Cardiology Centre, Milan (Italy)

7 More presentations in this session

Presentation thumbnail
Effects of left atrial to coronary sinus shunting on right heart function: the ALT-FLOW early feasibility study (EFS) one-year results
Associate Professor M. Urey (San Diego, US)
Abstract Slides Video
Presentation thumbnail
The efficacy and safety of heart failure treatment according to frailty status; a systematic review.
Miss C. Nijskens (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Heart failure in elderly patients with a recent myocardial infarction and the effect of omega-3 fatty acids: secondary analysis from the OMEMI trial
Doctor K. Berge (Nordbyhagen, NO)
Abstract Slides Video
Presentation thumbnail
First-in-human study of left ventricular remuscularization with induced pluripotent stem cell derived cardiomyocyte spheroids for severe ischemic heart failure patients: preliminary LAPiS study result
Assistant Professor Y. Ichihara (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Cardiac rhythm management devices in patients with heart failure - preliminary results of the DIRECT HF international survey on healthcare professionals' educational needs
Professor S. Zieroth (Winnipeg, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 1

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies
thumbnail
Congress Presentation
Dapaglifozin in advanced heart failure patients : effects on congestion, NTproBNP and cardiorenal outcome
thumbnail
Congress Presentation
Effect of dapagliflozin on ventilatory control during low-intensity exercise in heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources